ArticleCureus2026
Repeated Abscopal Effect After Two Courses of Stereotactic Body Radiotherapy for Multiple Postoperative Metastases of Malignant Melanoma of the Buccal Mucosa.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of repeated abscopal effect (AE) following two courses of stereotactic body radiotherapy (SBRT) for multiple postoperative metastases of malignant melanoma in the buccal mucosa during treatment with nivolumab. A 90-year-old female presented with malignant melanoma of the right buccal mucosa. She underwent partial resection of the right buccal mucosa and right cervical dissection at our hospital in January 2022. In August 2022, positron emission tomography (PET)-CT revealed recurrence in the left cervical lymph node and metastatic lung tumors at S5 of the left lung and S9 of the right lung. SBRT (40 Gy in five fractions) was performed for the recurrent left cervical lymph node. In December 2022, PET-CT showed regression of the irradiated lymph nodes as well as an unirradiated left lung S5 lesion, which was considered the first AE. In addition to the existing S9 lesion in the right lung, a new metastatic lung tumor was identified in S4 of the right lung, and SBRT of 42 Gy in four fractions was performed on the right S9 lesion in April 2023. In July 2023, PET-CT showed regression of both the irradiated right S9 lesion and the unirradiated right S4 lesion, representing the second AE. Both the irradiated and unirradiated lesions associated with AE remained reduced on PET-CT in October 2023. Repeated AEs after two SBRT courses during nivolumab therapy are extremely rare. We report this case together with a literature review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.